Cellectar Biosciences, Inc(NASDAQ:CLRB) 
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refr...
Website: http://www.cellectar.com
Founded: 1996
Full Time Employees: 8
Sector: Healthcare
Industry: Biotechnology
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-06-30 | 2013-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
operating expenses: | ||||||||||||||||||||||||||||||||||||||||||||||||
research and development | 3,007,229 | 3,158,561 | 2,523,305 | 2,389,801 | 3,427,095 | 6,209,227 | 5,493,496 | 7,345,480 | 7,377,940 | 7,936,456 | 7,312,504 | 6,308,430 | 6,654,094 | 5,453,757 | 5,380,190 | 4,498,657 | 3,887,039 | 4,388,175 | 3,937,464 | 4,627,636 | 2,375,008 | 2,683,944 | 2,465,392 | 2,616,337 | 2,174,283 | 2,703,831 | 1,809,547 | 2,308,397 | 1,036,703 | 1,995,571 | 1,723,087 | 2,124,060 | 3,099,798 | 2,333,058 | 2,175,929 | 1,856,880 | 1,039,454 | 964,147 | 1,167,768 | 1,382,966 | 1,643,994 | 1,398,050 | 1,470,297 | 1,380,798 | 1,715,307 | 1,648,838 | 1,590,613 | |
general and administrative | 2,786,713 | 2,532,068 | 2,327,391 | 3,647,728 | 2,973,896 | 6,535,599 | 7,834,181 | 6,358,229 | 4,623,546 | 4,611,423 | 2,100,956 | 1,985,572 | 2,051,207 | 1,968,779 | 2,435,296 | 2,936,867 | 2,253,188 | 1,535,230 | 1,882,190 | 1,401,053 | 1,424,515 | 1,225,993 | 1,156,842 | 1,342,318 | 1,210,291 | 1,260,048 | 1,390,812 | 1,321,415 | 1,172,661 | 1,091,921 | 1,181,832 | 1,329,467 | 988,699 | 1,150,710 | 1,040,540 | 955,356 | 961,254 | 799,381 | 834,888 | 817,657 | 943,433 | 854,962 | 802,794 | 959,885 | 1,087,035 | 1,073,749 | 1,121,703 | |
total operating expenses | 5,793,942 | 5,690,629 | 4,850,696 | 6,037,529 | 6,400,991 | 12,744,826 | 13,327,677 | 13,703,709 | ||||||||||||||||||||||||||||||||||||||||
income from operations | -5,793,942 | -5,690,629 | -4,850,696 | -6,037,529 | -6,400,991 | -12,744,826 | -13,327,677 | -13,703,709 | -12,001,486 | -12,547,879 | -9,413,460 | -8,294,002 | -8,705,301 | -7,422,536 | -7,815,486 | -7,435,524 | -6,140,227 | -5,923,405 | -5,819,654 | -6,028,689 | -3,799,523 | -3,909,937 | -3,622,234 | -3,958,655 | -3,384,574 | -3,963,879 | -3,200,359 | -3,629,812 | -3,884,826 | -3,087,492 | -2,904,919 | -3,453,527 | -4,088,497 | -3,483,768 | -3,216,469 | -2,812,236 | -2,000,708 | -1,786,811 | -2,092,504 | -2,291,123 | -2,587,427 | -2,253,013 | -2,273,091 | -2,545,617 | -2,819,224 | -2,722,587 | -2,712,316 | |
yoy | -9.48% | -55.35% | -63.60% | -55.94% | -46.67% | 1.57% | 41.58% | 65.22% | 37.86% | 69.05% | 20.45% | 11.55% | 41.77% | 25.31% | 34.29% | 23.34% | 61.61% | 51.50% | 60.66% | 52.29% | 12.26% | -1.36% | 13.18% | 9.06% | -12.88% | 28.39% | 10.17% | 5.10% | -4.98% | -11.37% | -9.69% | 22.80% | 74.13% | 80.01% | 34.40% | -22.68% | -20.69% | -7.94% | -10.00% | -8.22% | -17.25% | -16.19% | ||||||
qoq | 1.82% | 17.32% | -19.66% | -5.68% | -49.78% | -4.37% | -2.74% | 14.18% | -4.35% | 33.30% | 13.50% | -4.72% | 17.28% | -5.03% | 5.11% | 21.10% | 3.66% | 1.78% | -3.47% | 58.67% | -2.82% | 7.94% | -8.50% | 16.96% | -14.61% | 23.86% | -11.83% | -6.56% | 25.82% | 6.28% | -15.89% | -15.53% | 17.36% | 8.31% | 14.37% | 11.97% | -14.61% | -8.67% | -11.45% | 14.84% | -0.88% | -10.71% | -9.71% | 3.55% | 0.38% | |||
other income: | ||||||||||||||||||||||||||||||||||||||||||||||||
gain on valuation of warrants | 77,000 | 297,833 | 294,276 | 501,598 | 10,211,243 | 6,088,355 | 12,455,431 | |||||||||||||||||||||||||||||||||||||||||
interest income | 62,996 | 97,575 | 112,543 | 88,020 | 136,962 | 244,210 | 317,887 | 328,907 | 319,849 | 139,222 | 51,110 | 72,780 | 124,034 | 147,444 | 4,164 | 481 | 430 | -1,327 | 590 | 659 | -833 | 374 | 10,309 | 1,047 | 4,671 | 14,072 | 11,798 | 12,171 | 14,247 | 6,558 | 4,228 | 4,654 | 4,308 | 3,969 | 4,941 | 3,387 | 549 | -228.25 | 617 | 449 | ||||||||
total other income | 139,996 | 395,408 | 406,819 | 589,618 | 12,784,338 | -9,580,151 | 5,039,222 | -4,318,890 | 72,780 | 124,034 | 147,444 | 4,164 | 481 | 430 | 5,307 | 590 | 659 | 184,447 | 374 | 10,309 | 1,047 | 4,671 | 60,072 | 12,798 | 8,171 | 57,247 | 72,558 | -22,296 | 9,758 | 13,069 | 94,941 | -79,088 | 2,825,271 | 2,737,724 | 234,266 | 4,573 | 286,271 | -318,417 | 1,767,375 | 459,781 | -124,189 | 658,125 | ||||||
net income | -5,653,946 | -5,295,221 | -4,443,877 | -5,447,911 | -6,604,029 | -2,355,373 | -14,664,719 | -919,371 | -21,581,637 | -7,448,657 | -13,732,350 | -8,221,222 | -8,581,267 | -7,215,092 | -7,811,322 | -7,435,043 | -6,139,797 | -5,918,098 | -5,819,064 | -6,028,030 | -3,615,076 | -3,909,563 | -3,611,925 | -3,957,608 | -3,379,903 | -3,903,807 | -3,187,561 | -3,621,641 | -3,827,579 | -3,014,934 | -2,920,691 | -3,475,823 | -4,078,739 | -3,470,699 | -3,121,528 | -2,891,324 | 824,563 | 950,913 | -1,858,238 | -2,286,550 | -2,301,156 | -2,571,430 | -505,716 | -2,085,836 | -2,943,413 | -2,064,462 | -3,453,879 | |
yoy | -14.39% | 124.81% | -69.70% | 492.57% | -69.40% | -68.38% | 6.79% | -88.82% | 151.50% | 3.24% | 75.80% | 10.57% | 39.76% | 21.92% | 34.24% | 23.34% | 69.84% | 51.37% | 61.11% | 52.31% | 6.96% | 0.15% | 13.31% | 9.28% | -11.70% | 29.48% | 9.14% | 4.20% | -6.16% | -13.13% | -6.43% | 20.22% | -520.91% | -428.27% | 55.59% | -135.83% | -136.98% | 267.45% | 9.62% | -21.82% | 24.56% | -85.36% | ||||||
qoq | 6.77% | 19.16% | -18.43% | -17.51% | 180.38% | -83.94% | 1495.08% | -95.74% | 189.74% | -45.76% | 67.04% | -4.20% | 18.93% | -7.63% | 5.06% | 21.10% | 3.75% | 1.70% | -3.47% | 66.75% | -7.53% | 8.24% | -8.73% | 17.09% | -13.42% | 22.47% | -11.99% | -5.38% | 26.95% | 3.23% | -15.97% | -14.78% | 17.52% | 11.19% | 7.96% | -13.29% | -151.17% | -18.73% | -0.63% | -10.51% | 408.47% | -75.75% | -29.14% | 42.58% | -40.23% | |||
net income per share | -1.33 | -0.53 | -1.41 | -3.39 | -0.14 | -0.01 | -0.37 | -0.03 | ||||||||||||||||||||||||||||||||||||||||
weighted-average common shares outstanding — basic and diluted | 4,240,129 | 46,079,875 | ||||||||||||||||||||||||||||||||||||||||||||||
warrant issuance expense | -7,743,284 | -470,000 | ||||||||||||||||||||||||||||||||||||||||||||||
weighted-average common shares outstanding — basic | 2,608,317 | 3,162,040 | 1,608,799 | 36,622,474 | 39,335,924 | 35,819,428 | ||||||||||||||||||||||||||||||||||||||||||
weighted-average common shares outstanding — diluted | 2,608,317 | 3,162,040 | 1,608,799 | 37,143,769 | 39,794,220 | 37,446,311 | ||||||||||||||||||||||||||||||||||||||||||
loss on valuation of warrants | -340,000 | -9,900,000 | ||||||||||||||||||||||||||||||||||||||||||||||
total other expense | -203,038 | -798,300.25 | -1,337,042 | -741,563 | ||||||||||||||||||||||||||||||||||||||||||||
costs and expenses: | ||||||||||||||||||||||||||||||||||||||||||||||||
total costs and expenses | 12,001,486 | 12,547,879 | 9,413,460 | 8,294,002 | 8,705,301 | 7,422,536 | 7,815,486 | 7,435,524 | 6,140,227 | 5,923,405 | 5,819,654 | 6,028,689 | 3,799,523 | 3,909,937 | 3,622,234 | 3,958,655 | 3,384,574 | 3,963,879 | 3,200,359 | 3,629,812 | 3,884,826 | 3,087,492 | 2,904,919 | 3,453,527 | 4,088,497 | 3,483,768 | 3,216,469 | 2,812,236 | 2,000,708 | 1,786,811 | 2,092,504 | 2,291,123 | 2,587,427 | 2,253,013 | 2,273,091 | 2,545,617 | 2,819,224 | 2,722,587 | 2,712,316 | |||||||||
basic and diluted net loss attributable to common stockholders per common share | -0.74 | -0.4 | -1.21 | -0.73 | -0.76 | -0.55 | -1.28 | -1.22 | -0.1 | -0.09 | -0.1 | -0.11 | -0.07 | -0.15 | -0.26 | -0.42 | -0.46 | -0.76 | -0.21 | -0.05 | -0.04 | -0.07 | ||||||||||||||||||||||||||
shares used in computing basic and diluted net loss attributable to common stockholders per common share | 29,346,679 | 944,340 | 11,308,738 | 11,261,217 | 11,261,217 | 945,542 | 6,110,119 | 6,110,124 | 61,101,262 | 1,882,306 | 59,868,374 | 52,763,809 | 3,273,476 | 26,326,782 | 13,793,548 | 9,389,661 | 576,807 | 9,386,703 | 6,963,301 | 4,773,500 | 16,808,189 | 57,397,997 | 57,397,997 | 51,286,886 | ||||||||||||||||||||||||
loss on revaluation of warrants | -975,000 | -3,900,000 | ||||||||||||||||||||||||||||||||||||||||||||||
gain on revaluation of derivative warrants | 46,000 | 1,000 | 43,000 | 66,000 | -20,000 | 5,450 | 9,100 | 90,000 | -82,475 | 2,824,722 | 3,141,802 | 233,649 | 4,124 | 288,251 | -308,375 | 2,020,433 | 573,751 | -54,945 | 660,341 | 6,043 | ||||||||||||||||||||||||||||
loss on revaluation of derivative warrants | -4,000 | -26,950 | ||||||||||||||||||||||||||||||||||||||||||||||
deemed dividend on preferred stock | -2,241,795 | |||||||||||||||||||||||||||||||||||||||||||||||
net loss attributable to common stockholders | -3,379,903 | -3,903,807 | -3,827,579 | -5,256,729 | -2,943,413 | -2,064,462 | -3,453,879 | |||||||||||||||||||||||||||||||||||||||||
basic and diluted net loss per common share | -0.378 | -0.42 | -1.323 | -1.65 | -1.69 | -0.183 | -0.26 | -0.23 | -0.3 | -0.3 | -0.23 | -0.1 | -0.73 | |||||||||||||||||||||||||||||||||||
shares used in computing basic and diluted net loss per common share | 551,138.5 | 3,184,856 | 1,731,561 | 3,246,608.75 | 13,470,974 | 13,461,994 | 7,562,762 | 7,562,762 | 1,000,915 | 5,012,206 | 2,869,739 | |||||||||||||||||||||||||||||||||||||
total other income (expense) | -15,772 | |||||||||||||||||||||||||||||||||||||||||||||||
basic net income per common share | -0.24 | 0.96 | ||||||||||||||||||||||||||||||||||||||||||||||
shares used in computing basic net income per common share | 12,010,284 | 858,107 | ||||||||||||||||||||||||||||||||||||||||||||||
diluted net income per common share | -0.24 | |||||||||||||||||||||||||||||||||||||||||||||||
shares used in computing diluted net income per common share | 12,010,284 | |||||||||||||||||||||||||||||||||||||||||||||||
fully diluted net income per common share | 0.91 | |||||||||||||||||||||||||||||||||||||||||||||||
shares used in computing fully diluted net income per common share | 906,381 | |||||||||||||||||||||||||||||||||||||||||||||||
restructuring costs | 23,283 | 89,848 | 90,500 | 1 | 204,934 | 16,882 | ||||||||||||||||||||||||||||||||||||||||||
basic and diluted net income per common share | -0.213 | -0.25 | ||||||||||||||||||||||||||||||||||||||||||||||
shares used in computing basic and diluted net income per common share | 1,890,769.5 | 7,563,701 | ||||||||||||||||||||||||||||||||||||||||||||||
interest expense | -1,980 | -10,042 | -253,058 | -113,970 | -69,244 | -2,216 | -2,649 | |||||||||||||||||||||||||||||||||||||||||
loss on issuance of derivative warrants | -744,957 | |||||||||||||||||||||||||||||||||||||||||||||||
merger costs | ||||||||||||||||||||||||||||||||||||||||||||||||
grant income | ||||||||||||||||||||||||||||||||||||||||||||||||
other income | ||||||||||||||||||||||||||||||||||||||||||||||||
deemed dividend on warrants |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2013-12-31 | 2013-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | ||||||||||||||||||
current assets: | ||||||||||||||||||
cash and cash equivalents | 8,347,090 | 13,196,033 | 12,554,289 | 11,041,027 | 13,905,173 | 34,263,371 | 25,868,907 | 40,031,181 | 12,682,691 | 19,866,358 | 17,785,322 | 24,805,565 | 30,634,122 | 35,703,975 | 40,344,727 | 46,777,855 | 2,418,384 | 5,110,493 |
prepaid expenses and other current assets | 920,038 | 842,432 | 1,067,409 | 1,576,579 | 987,495 | 1,635,818 | 2,036,453 | 1,337,184 | 1,163,745 | 663,243 | 975,936 | 479,668 | 760,420 | 867,485 | 1,048,082 | 347,028 | 294,687 | 329,352 |
total current assets | 9,267,128 | 14,038,465 | 13,621,698 | 12,617,606 | 14,892,668 | 35,899,189 | 27,905,360 | 41,368,365 | 13,846,436 | 20,529,601 | 18,761,258 | 25,285,233 | 31,394,542 | 36,571,460 | 41,392,809 | 47,124,883 | 2,768,071 | 5,494,845 |
property, plant & equipment | 339,697 | 549,405 | 595,271 | 647,549 | 700,826 | 910,131 | 978,701 | |||||||||||
operating lease right-of-use asset | 1,483,156 | 360,671 | 380,841 | 400,248 | 418,916 | 454,166 | 470,816 | |||||||||||
other long-term assets | 29,780 | 29,780 | 29,780 | 29,780 | 29,780 | 29,780 | 29,780 | |||||||||||
total assets | 11,119,761 | 14,978,321 | 14,627,590 | 13,695,183 | 16,042,190 | 37,293,266 | 29,384,657 | 42,908,439 | 14,838,456 | 21,589,790 | 19,319,513 | 25,892,396 | 31,990,186 | 37,201,809 | 41,953,269 | 47,737,858 | 6,815,939 | 9,647,315 |
liabilities and stockholders’ equity | ||||||||||||||||||
current liabilities: | ||||||||||||||||||
accounts payable and accrued liabilities | 4,724,826 | 4,423,548 | 4,014,682 | 4,678,713 | 3,874,429 | 8,304,311 | 6,463,208 | 7,393,950 | 6,904,545 | 5,478,443 | 6,367,035 | 5,462,267 | 4,511,716 | 3,854,914 | 3,034,489 | 3,391,017 | 1,162,098 | 1,157,313 |
warrant liability | 149,000 | 226,000 | 801,650 | 1,095,926 | 2,058,000 | 11,929,242 | 8,627,597 | 8,800,000 | ||||||||||
lease liability, current | 100,189 | 96,034 | 92,022 | 88,146 | 80,821 | 77,348 | ||||||||||||
total current liabilities | 4,873,826 | 4,749,737 | 4,912,366 | 5,866,661 | 6,020,575 | 20,314,374 | 15,168,153 | 16,267,944 | 6,955,651 | 5,529,290 | 6,515,235 | 5,606,110 | 4,651,310 | 3,990,363 | 3,165,895 | 3,518,493 | 4,523,155 | 4,629,170 |
lease liability, net of current portion | 1,528,825 | 309,397 | 335,895 | 361,487 | 386,203 | 552,981 | 166,292 | |||||||||||
total liabilities | 6,402,651 | 5,059,134 | 5,248,261 | 6,228,148 | 6,406,778 | 20,746,303 | 15,621,661 | 16,742,293 | 7,503,995 | 6,082,271 | 6,569,004 | 5,698,324 | 4,781,024 | 4,156,655 | 3,367,865 | 3,754,551 | 5,116,389 | 5,221,024 |
commitments and contingencies | ||||||||||||||||||
mezzanine equity: | ||||||||||||||||||
series d preferred stock, 111.11 shares authorized, issued and outstanding as of march 31, 2026 and december 31, 2025 | 1,382,023 | |||||||||||||||||
stockholders’ equity: | ||||||||||||||||||
series e-2 preferred stock, 1,225.00 shares authorized; 35.60 shares issued and outstanding as of march 31, 2026 and december 31, 2025 | 520,778 | |||||||||||||||||
common stock, 0.00001 par value... | 42 | 42 | 32 | 18 | 461 | 406 | 358 | 332 | 97 | 94 | 61 | 61 | 611 | 611 | 611 | 553 | 574 | 574 |
additional paid-in capital | 277,601,713 | 277,149,844 | 271,314,776 | 264,958,619 | 261,678,642 | 246,536,080 | 234,859,383 | 248,151,681 | 194,032,651 | 193,624,445 | 183,652,376 | 183,284,617 | 182,864,114 | 182,560,309 | 182,182,461 | 174,505,736 | 52,758,544 | 51,536,776 |
accumulated deficit | -274,787,446 | -269,133,500 | -263,838,280 | -259,394,403 | -253,946,492 | -244,987,090 | -230,322,371 | -239,064,176 | -188,080,310 | -179,499,043 | -172,283,951 | -164,472,629 | -157,037,586 | -150,897,789 | -144,979,691 | -139,160,627 | ||
total stockholders’ equity | 3,335,087 | 8,537,164 | 7,997,306 | 6,085,012 | 8,253,389 | 15,164,940 | 26,166,146 | 7,334,461 | 15,507,519 | 12,750,509 | 20,194,072 | 27,209,162 | 33,045,154 | 38,585,404 | 43,983,307 | 1,699,550 | 4,426,291 | |
total liabilities and stockholders’ equity | 11,119,761 | 14,978,321 | 14,627,590 | 13,695,183 | 16,042,190 | 37,293,266 | 42,908,439 | 14,838,456 | 21,589,790 | 19,319,513 | 25,892,396 | 31,990,186 | 37,201,809 | 41,953,269 | 47,737,858 | 6,815,939 | 9,647,315 | |
liabilities and stockholders’ (deficit) equity | ||||||||||||||||||
series d convertible preferred stock, 111.11 shares authorized; 111.11 shares issued and outstanding as of december 31, 2025 and 2024 | 1,382,023 | |||||||||||||||||
series e-2 preferred stock, 1,225.00 shares authorized; 35.60 and 35.60 shares issued and outstanding as of december 31, 2025 and 2024, respectively | 520,778 | |||||||||||||||||
series d preferred stock, 111.11 shares authorized, issued and outstanding as of september 30, 2025 and december 31, 2024 | 1,382,023 | |||||||||||||||||
series e-2 preferred stock, 1,225 shares authorized; 35.60 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 520,778 | |||||||||||||||||
series d preferred stock, 111.11 shares authorized, issued and outstanding as of june 30, 2025 and december 31, 2024 | 1,382,023 | |||||||||||||||||
stockholders’ equity | ||||||||||||||||||
series e-2 preferred stock, 1,225 shares authorized; 35.60 shares issued and outstanding as of june 30, 2025 and december 31, 2024, respectively | 520,778 | |||||||||||||||||
series d preferred stock, 111.11 shares authorized, issued and outstanding as of march 31, 2025 and december 31, 2024 | 1,382,023 | |||||||||||||||||
series e-2 preferred stock, 1,225.00 shares authorized; 35.60 shares issued and outstanding as of march 31, 2025 and december 31, 2024, respectively | 520,778 | |||||||||||||||||
long-term lease liability, net of current portion | 431,929 | 453,508 | 474,349 | 548,344 | 53,769 | 92,214 | 129,714 | |||||||||||
series d preferred stock, 111.11 shares authorized, issued and outstanding as of september 30, 2024 and december 31, 2023 | 1,382,023 | |||||||||||||||||
series e-2 preferred stock, 1,225.00 shares authorized; 149.60 and 319.76 shares issued and outstanding as of september 30, 2024 and december 31, 2023, respectively | 2,188,434 | |||||||||||||||||
series e-3 preferred stock, 2,205.00 shares authorized; 202.50 and 0 shares issued and outstanding as of september 30, 2024 and december 31, 2023, respectively | 4,369,317 | |||||||||||||||||
series e-4 preferred stock, 1,715.00 shares authorized; 714.00 and 0 shares issued and outstanding as of september 30, 2024 and december 31, 2023, respectively | 7,057,793 | |||||||||||||||||
series d preferred stock, 111.11 shares authorized, issued and outstanding as of june 30, 2024 and december 31, 2023 | 1,382,023 | |||||||||||||||||
stockholders’ (deficit) equity: | ||||||||||||||||||
series e-2 preferred stock, 1,225.00 shares authorized; 237.50 and 319.76 shares issued and outstanding as of june 30, 2024 and december 31, 2023, respectively | 3,474,286 | |||||||||||||||||
series e-3 preferred stock, 2,205.00 shares authorized; 202.50 and 0 shares issued and outstanding as of june 30, 2024 and december 31, 2023, respectively | 4,369,317 | |||||||||||||||||
total stockholders’ (deficit) equity | 12,380,973 | |||||||||||||||||
total liabilities and stockholders’ (deficit) equity | 29,384,657 | |||||||||||||||||
fixed assets | 1,023,447 | 376,084 | 418,641 | 338,944 | 364,838 | 331,144 | 344,491 | 254,041 | 286,768 | 2,360,534 | 2,449,786 | |||||||
right-of-use asset | 486,847 | 546,505 | 560,334 | 138,097 | 161,111 | 183,286 | 204,644 | 225,205 | 244,993 | |||||||||
long-term assets | 23,566 | 63,217 | 75,000 | 75,000 | 75,000 | 75,000 | ||||||||||||
other assets | 6,214 | 6,214 | 6,214 | 6,214 | 6,214 | 6,214 | 11,872 | 27,222 | ||||||||||
lease liability | 73,994 | 51,106 | 50,847 | 148,200 | 143,843 | 139,594 | 135,449 | 131,406 | 127,476 | |||||||||
series d preferred stock, 111.11 shares authorized, issued and outstanding as of march 31, 2024 and december 31, 2023 | 1,382,023 | |||||||||||||||||
series e-2 preferred stock, 1,225.00 shares authorized; 237.50 and 319.76 shares issued and outstanding as of march 31, 2024 and december 31, 2023, respectively | 3,474,286 | |||||||||||||||||
series e-3 preferred stock, 2,205.00 shares authorized; 630.00 and 0 shares issued and outstanding as of march 31, 2024 and december 31, 2023, respectively | 12,222,000 | |||||||||||||||||
preferred stock, 0.00001 par value... | 1,382,023 | 1,382,023 | 1,382,023 | 1,382,023 | ||||||||||||||
series d preferred stock: 111 shares issued and outstanding as of december 31, 2022 and 2021, respectively | 1,382,023 | |||||||||||||||||
long-term and other assets | 81,214 | 81,214 | 81,214 | |||||||||||||||
series d preferred stock: 111 and 1,519 shares issued and outstanding as of december 31, 2021 and 2020, respectively | 1,382,023 | |||||||||||||||||
long-term lease liability | 201,970 | 236,058 | ||||||||||||||||
series d preferred stock: 111 and 1,519 issued and outstanding as of september 30, 2021 and december 31, 2020, respectively | 1,382,023 | |||||||||||||||||
series d preferred stock: 695 and 1,519 issued and outstanding as of june 30, 2021 and december 31, 2020 respectively | 8,637,645 | |||||||||||||||||
restricted cash | 55,000 | 55,000 | ||||||||||||||||
deferred financing | ||||||||||||||||||
goodwill | 1,675,462 | 1,675,462 | ||||||||||||||||
derivative liability | 3,359,363 | 3,469,548 | ||||||||||||||||
capital lease obligations, current portion | 1,694 | 2,309 | ||||||||||||||||
long-term liabilities: | ||||||||||||||||||
notes payable | 450,000 | 450,000 | ||||||||||||||||
deferred rent | 143,234 | 141,854 | ||||||||||||||||
capital lease obligations, net of current portion | ||||||||||||||||||
total long-term liabilities | 593,234 | 591,854 | ||||||||||||||||
deficit accumulated during the development stage | -51,059,568 | -47,111,059 | ||||||||||||||||
deferred financing costs |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||
net loss | -5,653,946 | -5,295,221 | -4,443,876 | -5,447,911 | -6,604,029 | -2,355,373 | -14,664,718 | -5,979,718 | -21,581,637 | -7,448,657 | -13,732,350 | -8,221,222 | -8,581,267 | -7,215,092 | -7,811,322 | -7,435,043 | -6,139,797 | -5,918,098 | -5,819,064 | -6,028,030 | -6,357,170 | -3,615,076 | -3,909,563 | -3,611,925 | -3,957,608 | -3,379,903 | -3,903,807 | -3,187,561 | -3,621,641 | -3,827,579 | -3,014,934 | -2,920,691 | -3,475,823 | -4,078,739 | -3,470,698 | 950,913 | -1,858,237 | -2,286,550 | -2,301,156 | -2,571,430 | -505,716 | -2,085,836 | -2,943,413 | -3,948,509 | -1,315,318 | -2,064,462 | -3,453,879 | |||
adjustments to reconcile net loss to cash from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||
depreciation and amortization | -110,018 | 49,461 | 52,277 | 55,564 | 56,295 | 68,571 | 68,571 | 66,021 | 88,490 | 69,960 | 41,208 | 38,650 | 42,557 | 38,159 | 32,960 | 33,899 | 43,417 | 39,291 | 36,789 | 38,705 | 35,130 | 35,924 | 35,926 | 35,667 | 33,936 | 32,582 | 33,869 | 33,614 | 32,733 | 32,214 | 15,883 | 16,867 | 17,301 | 1,251,853 | 105,870 | 101,414 | 86,911 | 90,773 | 90,994 | 90,772 | 90,692 | 90,044 | 89,509 | 89,319 | 92,321 | 96,048 | 99,098 | 105,692 | 108,094 | 111,874 |
stock-based compensation expense | 451,869 | 567,788 | 565,391 | 562,737 | 1,534,053 | 799,250 | 454,363 | 497,878 | 419,757 | 408,206 | 367,759 | 419,953 | 303,805 | 421,161 | 200,617 | 124,564 | 116,292 | 92,643 | 144,146 | 149,774 | 301,471 | 207,654 | 163,896 | 175,579 | 173,438 | 176,324 | 231,086 | 165,674 | 102,918 | 165,016 | 71,755 | 191,790 | 146,559 | |||||||||||||||||
change in operating lease right-of-use asset | -3,246 | 20,169 | 19,407 | 18,668 | 17,958 | 17,292 | 16,650 | |||||||||||||||||||||||||||||||||||||||||||
change in fair value of warrants | -77,000 | -297,833 | -294,276 | -501,598 | 340,000 | -10,211,243 | -6,088,355 | |||||||||||||||||||||||||||||||||||||||||||
changes in: | ||||||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses and other current assets | 245,498 | 509,170 | -589,084 | -25,830 | 400,635 | -699,269 | -448,959 | 235,242 | -666,788 | 746,717 | -488,719 | 312,693 | -496,268 | 280,752 | 107,065 | 180,597 | -701,053 | 427,857 | -454 | 186,475 | -367,316 | 177,747 | -386 | 201,718 | 361,177 | -729,196 | 36,568 | 44,749 | -464,369 | 82,591 | 107,984 | -24,093 | 102,835 | -63,553 | -199,616 | 55,793 | 86,411 | -197,036 | 52,436 | 49,586 | 69,741 | -127,780 | 49,771 | 82,344 | 50,015 | -181,983 | 44,475 | 135,549 | ||
lease liability | -22,343 | -21,580 | -20,840 | -19,654 | -18,747 | -18,106 | -17,487 | -4,639 | -16,031 | -15,483 | -14,954 | -4,378 | -44,263 | -34,088 | -33,251 | -32,433 | -31,635 | -30,158 | -29,417 | -28,693 | -27,988 | -26,615 | -25,960 | -25,322 | -24,700 | -23,420 | -22,845 | -10,998 | ||||||||||||||||||||||
accounts payable and accrued liabilities | 301,278 | 408,866 | -664,031 | 804,284 | -3,710,911 | -718,971 | 1,841,103 | -930,742 | -1,784,695 | 1,364,056 | 1,422,916 | -512,872 | 1,426,102 | -888,592 | 904,768 | 950,551 | 656,802 | 820,425 | -356,528 | -1,504,964 | 1,452,784 | -394,841 | 632,277 | 265,646 | 277,522 | -211,469 | 347,325 | 472,942 | 511,256 | -962,586 | 477,904 | 209,863 | 16,025 | -151,473 | 552,934 | 280,205 | -230,341 | -67,256 | 96,003 | -132,300 | -112,019 | -109,748 | -205,516 | -55,914 | 203,071 | -169,751 | 4,785 | 135,839 | 158,485 | 145,999 |
cash from operating activities | -4,845,565 | -4,344,136 | -4,275,121 | -5,115,526 | -9,383,434 | -10,913,478 | -9,166,883 | -14,140,999 | -13,361,641 | -9,595,700 | -8,067,885 | -7,529,719 | -7,183,670 | -7,411,763 | -7,013,177 | -5,757,578 | -5,039,783 | -4,511,012 | -6,429,065 | -6,876,182 | -4,752,579 | -3,868,709 | -3,502,063 | -3,049,901 | -3,512,070 | -2,681,165 | -3,544,358 | -2,652,910 | -2,815,275 | -2,743,500 | -2,968,956 | -2,545,531 | -3,184,105 | -2,826,067 | -2,543,204 | -2,663,593 | -2,987,437 | -1,818,256 | -1,494,334 | -2,165,038 | -2,187,270 | -2,366,338 | -2,141,206 | -2,096,933 | -2,007,740 | -2,594,600 | -2,678,638 | -2,553,409 | -2,033,660 | -1,888,937 |
capital expenditures | -3,378 | 0 | 0 | 0 | -61,286 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
free cash flows | -4,848,943 | -4,344,136 | -4,275,121 | -5,115,526 | -10,974,764 | -9,166,883 | -14,140,999 | -13,361,641 | -9,595,700 | -8,067,885 | -7,529,719 | -7,183,670 | -7,411,763 | -7,013,177 | -5,757,578 | -5,039,783 | -4,511,012 | -6,429,065 | -6,876,182 | -4,752,579 | -3,868,709 | -3,502,063 | -3,049,901 | -3,512,070 | -2,681,165 | -3,544,358 | -2,652,910 | -2,815,275 | -2,743,500 | -2,968,956 | -2,545,531 | -3,184,105 | -2,826,067 | -2,543,204 | -2,663,593 | -2,987,437 | -1,818,256 | -1,494,334 | -2,165,038 | -2,187,270 | -2,366,338 | -2,141,206 | -2,096,933 | -2,007,740 | -2,594,600 | -2,678,638 | -2,553,409 | -2,033,660 | -1,888,937 | |
cash flows from investing activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||
purchases of property, plant & equipment | -3,378 | -61,286 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
cash from investing activities | -3,378 | -61,286 | 0 | -21,276 | -21,633 | -266,756 | -117,856 | -7,066 | -70,979 | -30,070 | -129,739 | -4,063 | -17,210 | 0 | -34,590 | -10,553 | -5,725 | -3,093 | -9,482 | -6,242 | -373,568 | 45,000 | 0 | -1,425 | 0 | -26,193 | -254,209 | -66,301 | -18,683 | -6,122 | -8,199 | -25,466 | -12,172 | -2,206 | 0 | -15,191 | -12,856 | 1,836,253 | 28 | 28,763 | ||||||||||
cash flows from financing activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||
net increase in cash and cash equivalents | -4,848,943 | 1,513,262 | -2,864,146 | -9,383,434 | 8,394,464 | -6,433,128 | -3,608,259 | -2,650,846 | ||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at beginning of period | 13,196,033 | 0 | 0 | 0 | 23,288,607 | 0 | 0 | 0 | 9,564,988 | 0 | 0 | 0 | 19,866,358 | 0 | 0 | 0 | 35,703,975 | 0 | 0 | 57,165,377 | 0 | 0 | 0 | 11,444,619 | ||||||||||||||||||||||||||
cash and cash equivalents at end of period | 8,347,090 | 641,744 | 1,513,262 | -2,864,146 | 13,905,173 | -10,974,764 | 8,394,464 | -14,162,274 | 40,031,181 | -9,421,455 | 13,833,471 | -7,529,719 | 12,682,691 | 2,081,036 | -7,020,243 | -5,828,557 | 30,634,122 | -6,433,128 | -6,848,867 | 53,626,722 | -3,608,259 | -2,650,846 | -2,925,321 | 11,238,394 | ||||||||||||||||||||||||||
supplemental disclosure of cash flow information | ||||||||||||||||||||||||||||||||||||||||||||||||||
right of use asset obtained in exchange for operating lease liability | 1,119,239 | |||||||||||||||||||||||||||||||||||||||||||||||||
stock-based compensation | 262,526 | 1,221,768 | 297,674 | 377,893 | 425,898 | |||||||||||||||||||||||||||||||||||||||||||||
loss on disposal of assets | ||||||||||||||||||||||||||||||||||||||||||||||||||
warrant issuance expense | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses and other assets | ||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from exercise of warrants and new warrants, net of issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock, pre-funded warrants and common warrants, net of issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||||||
cash from financing activities | 4,991,760 | 5,788,383 | 0 | 17,561,347 | 1 | 43,849,467 | 441,001 | 22,498,638 | 0 | 3 | -1 | 0 | 34,874 | 1,213,924 | 42,209,352 | -106,196 | 0 | -568 | 9,023,735 | -811 | -790 | 15,116,686 | -93,888 | -728 | 7,170,261 | -81,449 | -7,519 | 2,847,513 | -131,160 | 2,898,281 | -189,590 | -866 | -1,211 | 0 | 12,049,119 | -174,202 | 3,999,374 | -615 | -604 | -594 | 5,045,108 | |||||||||
increase in cash and cash equivalents | ||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosure of non-cash information | ||||||||||||||||||||||||||||||||||||||||||||||||||
conversion of preferred stock to common stock | 13,094,767 | 14,502,009 | 8,293,365 | 31,758,346 | 0 | 7,255,622 | 3,109,552 | 8,288,652 | ||||||||||||||||||||||||||||||||||||||||||
settlement of warrants to equity | 275,565 | 0 | 5,198,199 | 2,610,000 | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from exercise of warrants, net of issuance costs | 0 | 17,561,347 | 1 | 43,849,467 | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock and pre-funded warrants, net of issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of common stock in connection with exercise of pre-funded warrants | ||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of stock and warrants, net of issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from exercise of warrants | 441,001 | 0 | 0 | 0 | 1,213,924 | 22,500 | 6,000 | 2,934,759 | ||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of preferred stock and warrants, net of issuance costs | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||
loss on revaluation of warrants | 9,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
noncash lease expense | 15,436 | 15,283 | 14,734 | 14,205 | 13,829 | 23,885 | 23,014 | 22,175 | 21,358 | 20,561 | 19,788 | 19,050 | 18,322 | 17,617 | 16,936 | 16,281 | 15,642 | 15,020 | 14,419 | 13,842 | 13,281 | |||||||||||||||||||||||||||||
purchases of fixed assets | -21,633 | -266,756 | -117,856 | -7,066 | -70,979 | -30,070 | -129,739 | -4,063 | -17,210 | 0 | -34,590 | -10,553 | -5,725 | -3,093 | -9,482 | -6,242 | -383,568 | 0 | 0 | -1,425 | 0 | -26,193 | -254,209 | -66,301 | -18,683 | -6,122 | -8,199 | -25,466 | -12,172 | -2,206 | 0 | -15,191 | -12,856 | -41,979 | 0 | -92,977 | ||||||||||||||
net decrease in cash and cash equivalents | 30,466,193 | 13,833,471 | -7,529,719 | -7,183,667 | -7,020,243 | -5,828,557 | -5,069,853 | |||||||||||||||||||||||||||||||||||||||||||
supplemental disclosure of cash flow information settlement of warrants to equity | 4,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
loss on disposal of asset | ||||||||||||||||||||||||||||||||||||||||||||||||||
costs to issue warrants | ||||||||||||||||||||||||||||||||||||||||||||||||||
gain on valuation of warrants | ||||||||||||||||||||||||||||||||||||||||||||||||||
decrease in cash and cash equivalents | ||||||||||||||||||||||||||||||||||||||||||||||||||
conversion of mezzanine equity to permanent equity | ||||||||||||||||||||||||||||||||||||||||||||||||||
loss on disposal of fixed assets | 0 | 0 | 0 | 2,938 | 583 | 0 | 0 | 858 | 0 | 1 | -1 | 2,269 | 3,010 | 0 | 0 | 4,513 | ||||||||||||||||||||||||||||||||||
proceeds from exercise of pre-funded warrants | 0 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock, net of underwriting issuance costs | -1 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock, net of issuance costs | 0 | 0 | 4,975,153 | |||||||||||||||||||||||||||||||||||||||||||||||
gain on extinguishment of debt | ||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from long-term obligations | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
increase in cash, cash equivalents, and restricted cash | ||||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents, and restricted cash at beginning of period | 10,614,722 | 0 | 0 | 0 | 13,310,616 | 10,061,421 | ||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents, and restricted cash at end of period | 7,092,099 | -2,686,890 | -3,548,019 | 6,361,343 | 10,488,288 | 6,875,163 | ||||||||||||||||||||||||||||||||||||||||||||
cash paid for interest expense | 0 | 0 | 0 | 1,584 | -1,056 | 1,056 | 0 | 880 | 0 | 0 | 0 | 364 | 1,467 | |||||||||||||||||||||||||||||||||||||
deferred issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||||||
net (decrease) in cash and cash equivalents | -3,538,655 | |||||||||||||||||||||||||||||||||||||||||||||||||
gain on revaluation of derivative warrants | 0 | -43,000 | -5,450 | -9,100 | -2,824,722 | -3,141,802 | -233,649 | 308,375 | -2,020,433 | |||||||||||||||||||||||||||||||||||||||||
other assets | ||||||||||||||||||||||||||||||||||||||||||||||||||
payments on capital lease obligations | 0 | -568 | -834 | -811 | -790 | -768 | -750 | -728 | -941 | -459 | -672 | -655 | -588 | -572 | -558 | -541 | -1,211 | 0 | -431 | -637 | -626 | -615 | -604 | -594 | -584 | |||||||||||||||||||||||||
proceeds from issuance of common stock and preferred stock, net of underwriting issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock and warrants, net of underwriting issuance costs | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of warrants | ||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of common stock in connection with exercise of warrants | ||||||||||||||||||||||||||||||||||||||||||||||||||
obtaining a right-of-use asset in exchange for a lease liability | 0 | 0 | 405,000 | |||||||||||||||||||||||||||||||||||||||||||||||
lease liability established through right-of-use asset | 0 | 0 | 609,000 | |||||||||||||||||||||||||||||||||||||||||||||||
loss on revaluation of derivative warrants | -1,000 | 4,000 | 20,000 | 26,950 | 82,475 | -288,251 | 54,945 | -1,597,372 | -660,341 | -6,043 | ||||||||||||||||||||||||||||||||||||||||
net decrease in cash, cash equivalents, and restricted cash | -3,522,623 | -3,548,019 | 6,361,343 | -2,822,328 | -3,186,258 | |||||||||||||||||||||||||||||||||||||||||||||
impairment of goodwill | ||||||||||||||||||||||||||||||||||||||||||||||||||
gain on disposal of fixed assets | ||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of fixed assets | 10,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
reverse stock split fractional shares | 0 | -594 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of preferred stock | ||||||||||||||||||||||||||||||||||||||||||||||||||
beneficial conversion feature and related deemed dividend on preferred stock | ||||||||||||||||||||||||||||||||||||||||||||||||||
gain on disposal of assets | ||||||||||||||||||||||||||||||||||||||||||||||||||
other assets and liabilities | 465,823 | 11,872 | -40,438 | -129,740 | -49,980 | -1,369 | -1,216 | -1,216 | -325 | 396 | 540 | 539 | 1,378 | |||||||||||||||||||||||||||||||||||||
proceeds from issuance of preferred stock, net of underwriting issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||||||
change in deferred issuance cost | ||||||||||||||||||||||||||||||||||||||||||||||||||
change in deferred issuance costs | -103,490 | 70,539 | ||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from conversion of warrants | ||||||||||||||||||||||||||||||||||||||||||||||||||
payments on long-term obligations | -60,528 | |||||||||||||||||||||||||||||||||||||||||||||||||
payments on notes payable | 0 | 0 | -86,591 | |||||||||||||||||||||||||||||||||||||||||||||||
net increase in cash, cash equivalents and restricted cash | ||||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash at beginning of period | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash at end of period | 12,192,730 | |||||||||||||||||||||||||||||||||||||||||||||||||
net (decrease) in cash, cash equivalents and restricted cash | ||||||||||||||||||||||||||||||||||||||||||||||||||
deferred rent | 1,380 | 1,380 | 2,059 | 2,196 | 2,195 | |||||||||||||||||||||||||||||||||||||||||||||
cash paid for issuance costs | -69,450 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
deferred financing costs | ||||||||||||||||||||||||||||||||||||||||||||||||||
reclassification to equity for warrants that are no longer derivative instruments | ||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid for reverse stock split fractional shares | ||||||||||||||||||||||||||||||||||||||||||||||||||
net income | -2,891,324 | 824,563 | ||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income to cash from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||
net decrease in cash and equivalents | -206,225 | -1,949,416 | ||||||||||||||||||||||||||||||||||||||||||||||||
loss on issuance of derivative warrants | 0 | 0 | 0 | 744,957 | ||||||||||||||||||||||||||||||||||||||||||||||
fair value of derivative warrants issued | ||||||||||||||||||||||||||||||||||||||||||||||||||
cash and equivalents at beginning of period | 3,857,791 | 0 | 0 | 9,422,627 | 0 | 0 | 2,418,384 | 0 | 0 | 4,677,545 | ||||||||||||||||||||||||||||||||||||||||
cash and equivalents at end of period | 1,908,375 | -2,360,750 | -2,196,335 | 7,029,612 | 9,949,980 | -2,181,942 | 3,807,967 | -717,760 | -2,034,226 | 7,862,479 | ||||||||||||||||||||||||||||||||||||||||
non-cash interest expense related to convertible debt | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of convertible notes | 0 | 4,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of notes payable | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||
payment of notes payable | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock and warrants | ||||||||||||||||||||||||||||||||||||||||||||||||||
exchange of debentures and accrued interest for common stock | -9 | |||||||||||||||||||||||||||||||||||||||||||||||||
fair value of warrants issued | ||||||||||||||||||||||||||||||||||||||||||||||||||
relative fair value of warrants issued with debentures | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||
asset acquired by the issuance of a capital lease | ||||||||||||||||||||||||||||||||||||||||||||||||||
long-term debt payments | -59,376 | |||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of convertible debentures | ||||||||||||||||||||||||||||||||||||||||||||||||||
payments of notes payable | ||||||||||||||||||||||||||||||||||||||||||||||||||
increase in cash and equivalents | -2,360,750 | -2,196,335 | -2,393,015 | 9,949,980 | -2,181,942 | 1,389,583 | -717,760 | -2,034,226 | 3,184,934 | |||||||||||||||||||||||||||||||||||||||||
fair value of warrants classified as derivative liability | 0 | 0 | 5,720,000 | |||||||||||||||||||||||||||||||||||||||||||||||
interest paid | 21,003 | |||||||||||||||||||||||||||||||||||||||||||||||||
change in restricted cash | 0 | 1,878,232 | 28 | 121,740 | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock and warrants, net of issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||||||
change in deferred financing costs | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
fair value of warrants classified as a derivative liability | ||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash interest expense related to discount on convertible debt | 31,753 | 19,052 | ||||||||||||||||||||||||||||||||||||||||||||||||
relative fair value of warrants issued with convertible debt | 0 | 254,024 | ||||||||||||||||||||||||||||||||||||||||||||||||
intrinsic value of beneficial conversion feature associated with convertible debt | ||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of stock for technology and services | ||||||||||||||||||||||||||||||||||||||||||||||||||
impairment of intangible assets | ||||||||||||||||||||||||||||||||||||||||||||||||||
accrued interest | ||||||||||||||||||||||||||||||||||||||||||||||||||
cash acquired in a business combination | ||||||||||||||||||||||||||||||||||||||||||||||||||
purchases of short-term certificates of deposit | ||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from short-term certificates of deposit | ||||||||||||||||||||||||||||||||||||||||||||||||||
payment for intangible assets | ||||||||||||||||||||||||||||||||||||||||||||||||||
repurchase of common stock | ||||||||||||||||||||||||||||||||||||||||||||||||||
cash in lieu of fractional shares in a business combination | ||||||||||||||||||||||||||||||||||||||||||||||||||
fair value of derivative warrants reclassified to equity upon cashless exercise | ||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of common stock in connection with the conversion of notes payable and 463,722 in accrued interest | ||||||||||||||||||||||||||||||||||||||||||||||||||
fair value of assets acquired in exchange for securities in a business combination | ||||||||||||||||||||||||||||||||||||||||||||||||||
fair value of liabilities assumed in exchange for securities in a business combination | ||||||||||||||||||||||||||||||||||||||||||||||||||
goodwill resulting from business combination | ||||||||||||||||||||||||||||||||||||||||||||||||||
loss on derivative warrants | ||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from exercise of warrant | ||||||||||||||||||||||||||||||||||||||||||||||||||
fair value of derivative warrants reclassified to additional paid-in capital upon cashless exercise | ||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of common stock in connection with the conversion of notes payable and accrued interest | ||||||||||||||||||||||||||||||||||||||||||||||||||
goodwill resulting from a business combination |